920 resultados para MARKOV-CHAINS


Relevância:

20.00% 20.00%

Publicador:

Resumo:

This master thesis deals with determining of innovative projects "viability". "Viability" is the probability of innovative project being implemented. Hidden Markov Models are used for evaluation of this factor. The problem of determining parameters of model, which produce given data sequence with the highest probability, are solving in this research. Data about innovative projects contained in reports of Russian programs "UMNIK", "START" and additional data obtained during study are used as input data for determining of model parameters. The Baum-Welch algorithm which is one implementation of expectation-maximization algorithm is used at this research for calculating model parameters. At the end part of the master thesis mathematical basics for practical implementation are given (in particular mathematical description of the algorithm and implementation methods for Markov models).

Relevância:

20.00% 20.00%

Publicador:

Resumo:

At head of title: U.S. Department of commerce. Roy D. Chapin, secretary. Bureau of the census. W. M. Steuart, director.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

1976 ed. issued under title: Variable regions of immunoglobulin chains.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

no. 2-4. No special title.--no. 5. Group selling by 100,000 retailers.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Mode of access: Internet.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Prepared under the auspices of the Survey Research Center.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Thesis (Master's)--University of Washington, 2016-06

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Background: A new immunoassay for free light chain measurements has been reported to be useful for the diagnosis and monitoring of monoclonal light chain diseases and nonsecretory myeloma. We describe experience with and some potential pitfalls of the assay. Methods: The assay was assessed for precision, sample type and stability, recovery, and harmonization of results between two analyzers on which the reagents are used. Free-light-chain concentrations were measured in healthy individuals (to determine biological variation), patients with monoclonal gammopathy of undetermined significance, myeloma patients after autologous stem cell transplants, and patients with renal disease. Results: Analytical imprecision (CV) was 6-11% for kappa and A free-light-chain measurement and 16% for the calculated kappa/lambda ratio. Biological variation was generally insignificant compared with analytical variation. Despite the same reagent source, values were not completely harmonized between assay systems and may produce discordant free-light-chain ratios. In some patients with clinically stable myeloma, or post transplantation, or with monoclonal gammopathy of undetermined significance, free-light-chain concentration and ratio were within the population reference interval despite the presence of monoclonal intact immunoglobulin in serum. In other patients with monoclonal gammopathy of undetermined significance, values were abnormal although there was no clinical evidence of progression to multiple myeloma. Conclusions: The use of free-light-chain measurements alone cannot differentiate some groups of patients with monoclonal gammopathy from healthy individuals. As with the introduction of any new test, it is essential that more scientific data about use of this assay in different subject groups are available so that results can be interpreted with clinical certainty. (C) 2003 American Association for Clinical Chemistry.